CONSEQUENCES OF LATE DIAGNOSIS OF LYMPHOMAS IN CHILDREN

2021 ◽  
Vol 100 (3) ◽  
pp. 166-174
Author(s):  
T.T. Valiev ◽  
◽  
N.V. Matinyan ◽  
N.A. Batmanova ◽  
Ya.A. Erdomaeva ◽  
...  
Keyword(s):  
Case Reports ◽  
Diagnostic Errors ◽  
Stage Iv ◽  
Large Cell ◽  
Infectious Complications ◽  
Malignant Neoplasms ◽  
Term Survival ◽  
Therapeutic Problem ◽  
Childhood Lymphoma

Lymphoma is the third leading cause of malignant neoplasms (MNs) in children. Childhood lymphoma is characterized by the prevalence of highly aggressive variants with high proliferation activity and rapid tumor dissimilation. Prolonged diagnosis becomes a reason of advanced-stage therapy. Despite the good results of long-term survival rate in patients, exceeding 90% even with late (III-IV) stages of lymphomas, the persistence of pathogenic (including multi-drug resistant) microorganisms in the patient's body becomes a major therapeutic problem, contamination of which occurs during the patient's stay in various medical organizations at the stage of diagnostics. The case reports of fatal infectious complications with the development of sepsis caused by polyresistant microorganisms in 2 children with anaplastic large cell lymphoma stage IV are presented in this article. Both case reports are unfavourable, despite the use of all medications and effective treatments. The analysis of diagnostic errors and necessity of cancer alarm generation in medical staff and patients' parents will make it possible to reduce the duration of diagnosis and probability of contamination of patient’s body with multi-resistant flora.

Long-term survival of a patient with stage IV pulmonary large cell carcinoma achieved by combined-modality therapy: Report of a case

Surgery Today ◽  
2000 ◽  
Vol 30 (6) ◽  
pp. 561-566
Author(s):  
Shunsuke Kobayashi ◽  
Shinichiro Okada ◽  
Toru Hasumi ◽  
Nobuyuki Sato ◽  
Shigefumi Fujimura
Keyword(s):  
Cell Carcinoma ◽  
Combined Modality Therapy ◽  
Stage Iv ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Term Survival ◽  
Long Term Survival ◽  
Combined Modality

scholarly journals Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma

2021 ◽  
pp. 910-918
Author(s):  
Masanori Takehara ◽  
Hiroshi Miyamoto ◽  
Yasuteru Fujino ◽  
Tetsu Tomonari ◽  
Tatsuya Taniguchi ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Median Overall Survival ◽  
Case Reports ◽  
Case Series ◽  
Stage Iv ◽  
Rare Type ◽  
Term Survival ◽  
Splenic Angiosarcoma ◽  
Line Chemotherapy

A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis.

Neutropenic enterocolitis.Two case reports of long-term survival following surgery

Cancer ◽  
1979 ◽  
Vol 43 (2) ◽  
pp. 730-734 ◽  
Author(s):  
Merrill S. Kies ◽  
Dan W. Luedke ◽  
James F. Boyd ◽  
Miles J. McCue
Keyword(s):  
Case Reports ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha

2018 ◽  
Vol 38 (11) ◽  
pp. 6393-6397 ◽  
Author(s):  
KALLE MATTILA ◽  
PIRITA RAANTA ◽  
VALTTERI LAHTELA ◽  
SEPPO PYRHÖNEN ◽  
ILKKA KOSKIVUO ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Combination Chemotherapy ◽  
Stage Iv ◽  
Term Survival ◽  
Long Term Survival ◽  
Melanoma Patients ◽  
Stage Iv Melanoma ◽  
Intermediate Dose

scholarly journals Long -Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation

2017 ◽  
Vol 50 (5) ◽  
pp. 491-494 ◽  
Author(s):  
Zachary Spiritos ◽  
Parit Mekaroonkamol ◽  
Bassel F. El Rayes ◽  
Seth D. Force ◽  
Steven A. Keilin ◽  
...  
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Stage Iv ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis

2021 ◽  
Vol 11 ◽  
Author(s):  
Tianwei Xu ◽  
Chenchen Wei ◽  
Xiaoteng Zou ◽  
Binbin Lu ◽  
Zhaoxia Wang
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Case Reports ◽  
Antiangiogenic Therapy ◽  
Local Treatment ◽  
Chemotherapy Resistance ◽  
Large Cell ◽  
Term Survival ◽  
Good Efficacy ◽  
Large Cell Lung Cancer

Undifferentiated large-cell lung cancer is a rare type of non-small cell lung cancer (NSCLC) with a poor prognosis. It is insensitive to chemotherapy and easily develops drug resistance. Analysis of the Surveillance, Epidemiology, and End Results (SEER) database showed that patients with stage IV undifferentiated large-cell lung cancer had a median overall survival (OS) of only 4 months and that those who received chemotherapy had a median OS of only 5 months longer than those who did not. For the first time, we report a case of advanced large-cell undifferentiated lung cancer with rare tonsil metastasis. The patient developed resistance after 3 months of platinum-based systemic chemotherapy and local treatment. Antiangiogenic therapy has been continuously progressing and has shown certain efficacy in treating many malignant tumors, such as lung cancer. However, there are no relevant studies or case reports on antiangiogenic therapy in the treatment of undifferentiated large-cell lung cancer. Anlotinib, an orally delivered small-molecule antiangiogenic tyrosine kinase inhibitor (TKI), was administered to this patient after chemotherapy resistance occurred, and the outcome was assessed as continued stable disease (SD). As of the last follow-up evaluation, the progression-free survival (PFS) of the patient was 21.5 months, and the OS was 27.5 months. Retrospective immunohistochemical analysis showed that the patient was positive for one of the targets of anlotinib (PDGFR). In general, the findings in this case suggest that anlotinib may be an option with good efficacy for patients with large-cell undifferentiated lung cancer after chemotherapy resistance that may have good efficacy and also suggest that PDGFR may be the target underlying this effect.

scholarly journals Pancreatic Resections in Renal Failure Patients: Is It Worth the Risk?

HPB Surgery ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
K. S. Norman ◽  
S. R. Domingo ◽  
L. L. Wong
Keyword(s):  
Renal Failure ◽  
Pancreatic Surgery ◽  
Case Reports ◽  
Case Series ◽  
Cardiovascular Complications ◽  
Improvement Program ◽  
Term Survival ◽  
Pancreatic Resections ◽  
American College Of Surgeons

Background. Chronic kidney disease affects 20 million US patients, with nearly 600,000 on dialysis. Long-term survival is limited and the risk of complex pancreatic surgery in this group is questionable. Previous studies are limited to case reports and small case series and a large database may help determine the true risk of pancreatic surgery in this population. Methods. The American College of Surgeons National Surgical Quality Improvement Program database was queried (2005–2011) for patients who underwent pancreatic resection. Renal failure was defined as the clinical condition associated with rapid, steadily increasing azotemia (rise in BUN) and increasing creatinine above 3 mg/dL. Operative trends and short-term outcomes were reviewed for those with and without renal failure (RF). Results. In 18,533 patients, 28 had RF. There was no difference in wound infections, neurologic or cardiovascular complications. Compared to non-RF patients, those with RF had more unplanned intubation (OR 4.89, 95% CI 1.85–12.89), bleeding requiring transfusion (OR 3.12, 95% CI 1.37–14.21), septic shock (OR 8.86, 95% CI 3.75–20.91), higher 30-day mortality (21.4% versus 2.3%, P<0.001) and longer hospital stay (23 versus 12 days, P<0.001). Conclusions. RF patients have much higher morbidity and mortality after pancreatic resections and surgeons should consider this before proceeding.

scholarly journals Risk of Complications and Survival of Patients Dialyzed with Permanent Catheters

Medicina ◽  
2019 ◽  
Vol 56 (1) ◽  
pp. 2
Author(s):  
Anna Szarnecka-Sojda ◽  
Wojciech Jacheć ◽  
Maciej Polewczyk ◽  
Agnieszka Łętek ◽  
Jarosław Miszczuk ◽  
...  
Keyword(s):  
Vascular Access ◽  
Infectious Complications ◽  
Term Survival ◽  
Long Term Survival ◽  
Dialysis Fistula ◽  
Study Population ◽  
Catheter Implantation ◽  
Stage Renal Disease ◽  
End Stage

Background and Objectives: An increase in the incidence of end-stage renal disease (ESRD) is associated with the need for a wider use of vascular access. Although arteriovenous (A-V) fistula is a preferred form of vascular access, for various reasons, permanent catheters are implanted in many patients. Materials and Methods: A retrospective analysis of clinical data was carried out in 398 patients (204 women) who in 2010–2016 were subjected to permanent dialysis catheters implantation as first vascular access or following A-V fistula dysfunction. The factors influencing the risk of complications related to vascular access and mortality were evaluated and the comparison of the group of patients with permanent catheter implantation after A-V fistula dysfunction with patients with first-time catheter implantation was carried out. Results: The population of 398 people with ESRD with mean age of 68.73 ± 13.26 years had a total of 495 permanent catheters implanted. In 129 (32.6%) patients, catheters were implanted after dysfunction of a previously formed dialysis fistula. An upward trend was recorded in the number of permanent catheters implanted in relation to A-V fistulas. Ninety-two infectious complications (23.1%) occurred in the study population in 65 patients (16.3%). Multivariate analysis showed that permanent catheters were more often used as the first vascular access option in elderly patients and cancer patients. Mortality in the mean 1.38 ± 1.17 years (min 0.0, max 6.70 years) follow-up period amounted to 50%. Older age and atherosclerosis were the main risk factors for mortality. Patients with dialysis fistula formed before the catheter implantation had a longer lifetime compared to the group in which the catheter was the first access. Conclusion: The use of permanent catheters for dialysis therapy is associated with a relatively high incidence of complications and low long-term survival. The main factors determining long-term survival were age and atherosclerosis. Better prognosis was demonstrated in patients after the use of A-V fistula as the first vascular access option.

Sign in / Sign up

Export Citation Format

Share Document